TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT05396651

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: low fodmap diet
Description: elimination of high fodmap diet - High FODMAP diet: ice cream, soft cheese , yoghurt, cabbage , cauliflower, green bean, garlic, okra, onions, snow peas, broccoli, avocado , apple, mango , dates, watermelon, legumes , pulses, wheat , pasta , artificial sweeteners

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: NICE guidelines for IBS
Description: follow NICE guidelines for IBS :have regular meals and take time to eat. avoid missing meals or leaving long gaps between eating. drink at least 8 cups of fluid per day, especially water or other non-caffeinated drinks, for example herbal teas.~restrict tea and coffee to 3 cups per day. reduce intake of alcohol and fizzy drinks.
Study: NCT00725270

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Mifepristone
Description: 600 mg of mifepristone

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo Oral Tablet
Description: Placebo comparator
Study: NCT03283475

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: thigh lift
Description: liposuction-assisted medial avulsion thighplasty enables technically refined contouring of the thigh and the possible preservation of the local microvasculature, which results in reduced complication rates
Study: NCT00685139

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Zonisamide 100 mg Capsule
Description: 100 mg capsule administered after an overnight fast.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Zonisamide (Zonegran®) 100 mg Capsule
Description: 100 mg capsule administered after an overnight fast.
Study: NCT04467918

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cannabidiol
Description: Already described

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: PLACEBO
Description: Already described
Study: NCT01202149

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Elidel (pimecrolimus cream, 1%) Hylatopic Plus Emollient Foam (non-medicated device)

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Elidel (pimecrolimus cream, 1%) Hylatopic Plus Emollient Foam (non-medicated device)
Study: NCT01978951

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Integrated Chronic Kidney Disease care
Description: Activities of integrated CKD care program, which will be provided during each hospital visit and quarterly home visits, are live demonstration about treatment and optimal diets for CKD patients, monitor drug compliance.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Conventional CKD care
Description: group counselling about optimal diets for CKD patients
Study: NCT00167804

Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Virtual Reality Exposure
Description: VRE uses computer generated environments to conduct exposure therapy.
Study: NCT03691077

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ocrelizumab
Description: The first dose of ocrelizumab will be administered as two 300-mg IV infusions (600 mg total) in 250 mL 0.9% sodium chloride each separated by 14 days (i.e., Days 1 and 15), followed by one 600-mg IV infusion in 500 mL 0.9% sodium chloride every subsequent doses (i.e., every 24 weeks) for 72 weeks.
Study: NCT03143647

Intervention type: OTHER
Intervention: Collect a study-specific blood sample of healthy subjects
Description: One heparin tube (4ml) and one hirudin tube (4ml) blood sample will be collected through standard venipuncture. After applying a tourniquet with moderate pressure around the arm of the patient's choice, skin will be disinfected over a suitable vein in the elbow or fore-arm. A hirudin and a heparin tube will be filled with venous blood through a single puncture with a 22 Ga needle (manufacturer, location). After release of the tourniquet, bleeding will be stopped by applying local pressure for 5 minutes with a sterile gauze.

Intervention type: OTHER
Intervention: Collect a study-specific blood sample of healthy subjects
Description: One heparin tube (4ml) and one hirudin tube (4ml) blood sample will be collected through standard venipuncture. After applying a tourniquet with moderate pressure around the arm of the patient's choice, skin will be disinfected over a suitable vein in the elbow or fore-arm. A hirudin and a heparin tube will be filled with venous blood through a single puncture with a 22 Ga needle (manufacturer, location). After release of the tourniquet, bleeding will be stopped by applying local pressure for 5 minutes with a sterile gauze.
Study: NCT01532804

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: bevacizumab, oxaliplatin and 5FU combination
Description: Bevacizumab 5 mg/kg administered as an iv infusion for 1h30, then for 1h and for 30 min. at the following cycles, respectively.~Oxaliplatin 85 mg/m² administered as an iv infusion for 2h Elvorine 200 mg/m² administered as an iv infusion for 2h 5FU 400 mg/m2 bolus then 5FU 2,400 mg/m² iv infusion for 46h D1=D15 (12 cycles)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bevacizumab, oxaliplatin and raltitrexed combination
Description: Bevacizumab 7.5 mg/kg administered as an iv infusion for 1h30, then administered for 1h and 30 min at the following cycles, respectively.~Oxaliplatin 130 mg/m² administered as an iv infusion for 2h Raltitrexed 3 mg/m² administered as an iv infusion for 15 min
Study: NCT00506246

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Propofol
Description: * intravenous (total intravenous anaesthesia)~* induction and maintenance

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Propofol
Description: * intravenous (total intravenous anaesthesia)~* induction and maintenance
Study: NCT00089960

Intervention type: DRUG
Group type: OTHER
Intervention: AMG 706
Description: AMG 706 125 mg daily for 48 weeks, or until progressive disease or unacceptable toxicity.
Study: NCT03523026

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Neuromuscular Electrical Stimulation
Description: Neuromuscular Electrical Stimulation(NMES) to rectus abdominis will be applied using 4 carbon silicon electrode. In the first sessions, patients ECG will be checked. Patients will be in semi-fowler position (30º),with their lower limbs to be in extension and upper limbs at their sides. The NMES frequency will be at 30 Hertz and the application time will be 30 minutes. Treatment will be programmed for 3 days per week. The patients will coordinate their breath (inspiration) with the contraction which will be generated by the electrical current. The program will continue for 6 weeks.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Inspirator Muscle Training
Description: Inspirator Muscle Training(IMT) will be applied 7 days per week, twice a day for 15 minutes. The program will continue for 6 weeks duration under weekly control of the investigator.Training intensity will set at 30% of the maximum inspiratory pressure.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Peripheral Muscle Training
Description: Peripheral Muscle Training will be applied by elastic band and Proprioceptive Neuromuscular Facilitation 3 times per week.The program will continue for 6 weeks.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Peripheral Muscle Training
Description: Peripheral Muscle Training will be applied by elastic band and Proprioceptive Neuromuscular Facilitation 3 times per week.The program will continue for 6 weeks.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Peripheral Muscle Training
Description: Peripheral Muscle Training will be applied by elastic band and Proprioceptive Neuromuscular Facilitation 3 times per week.The program will continue for 6 weeks.
Study: NCT04223804

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ABBV-181
Description: Intravenous (IV) Infusion

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ABBV-181
Description: Intravenous (IV) Infusion

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ABBV-181
Description: Intravenous (IV) Infusion

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Intravenous (IV) infusion

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Intravenous (IV) infusion
Study: NCT03236623

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Menthol Popsicle
Description: The menthol popsicle composed of 0.05% menthol, 0.05% saccharin, 30ml ultrafiltered water and 2% cereal alcohol. The popsicle will have a support that will assist the patient in the administration of the intervention, giving him autonomy and safety in the application of the intervention.
Study: NCT02456519

Intervention type: OTHER
Intervention: PaedQoR-15 questionnaire
Description: Children/ young people and one parent/ guardian will complete the questionnaire before and after general anaesthesia for surgery or diagnostic imaging.
Study: NCT02993406

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bempedoic acid 180 mg tablet
Description: Patients take bempedoic acid 180 mg tablet orally once daily

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Matching placebo tablet
Description: Patients take matching placebo tablet orally once daily
Study: NCT04829097

Intervention type: COMBINATION_PRODUCT
Group type: ACTIVE_COMPARATOR
Intervention: Temozolomide
Description: The patient received neoadjuvant temozolomide combined with simultaneous increase in intensity-modulated radiotherapy. According to data from previous clinical trials, neoadjuvant temozolomide combined with concurrently increased intensity-modulated radiotherapy PFS for 13.7 months.

Intervention type: COMBINATION_PRODUCT
Group type: EXPERIMENTAL
Intervention: Temozolomide
Description: The patient received neoadjuvant temozolomide combined with simultaneous increase in intensity-modulated radiotherapy. According to data from previous clinical trials, neoadjuvant temozolomide combined with concurrently increased intensity-modulated radiotherapy PFS for 13.7 months.
Study: NCT02919215

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Teacher Help Intervention
Description: The intervention will be provided to collaborating psychologists and their teachers to access. Teachers will work through the intervention, and psychologists will act as the online support for teachers. Teachers will work with one student in their classroom with ADHD, ASD, or LD throughout the intervention phase. Each session in the program will provide factual information to teachers, strategies for implementation of best practices to address the specific mental health disorder in the classroom setting (i.e., ADHD, ASD, or LD), and access to additional help and advice.
Study: NCT03076073

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Impact of physical activity on tendons
Description: Single vs. multiple (up to 12 weeks) of different types of physical exercises (aerobic vs. anaerobic activities).
Study: NCT03412851

Intervention type: OTHER
Intervention: A Direct Aspiration First Pass Technique
Description: Distal aspiration technique

Intervention type: OTHER
Intervention: Stentriever Thrombectomy
Description: Thrombectomy with stent retriever
Study: NCT01365936

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: HMG
Description: In this prospective trial, women with PCOS (according to Rotterdam criteria) were randomized (80 patients) after GnRH analogue suppression to stimulation with HMG (n=38) or rFSH (n=42) using a low dose step up protocol in ICSI cycles.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: rFSH
Description: Patients were randomized after GnRH analogue suppression to stimulation with HMG (n=38) or rFSH (n=42) using a low dose step up protocol in ICSI cycles.
Study: NCT04442100

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: valve prosthetics
Description: prosthetics of heart valves with dentures MedEng-Bio
Study: NCT04496245

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Broncho-Vaxom®
Description: Broncho-Vaxom adult capsules® (OM85)

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Broncho-Vaxom®
Description: Broncho-Vaxom adult capsules® (OM85)
Study: NCT00828113

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: varenicline
Description: Double-blind switch to placebo after 12 weeks of open-label therapy

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Individual smoking cessation counseling
Description: Brief (\<10 minutes) smoking cessation counseling delivered at clinic visits

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Individual smoking cessation counseling
Description: Brief (\<10 minutes) smoking cessation counseling delivered at clinic visits
Study: NCT05588986

Intervention type: OTHER
Intervention: ultrasonography
Description: Umbilical artery Doppler evaluation by ultrasonography just before the first dose of antenatal corticosteroid, 24 hours and 48 hours after the last dose.

Intervention type: OTHER
Intervention: ultrasonography
Description: Umbilical artery Doppler evaluation by ultrasonography just before the first dose of antenatal corticosteroid, 24 hours and 48 hours after the last dose.
Study: NCT01963884

Intervention type: PROCEDURE
Intervention: Tooth Extraction
Description: Tooth from the maxillary anterior area extracted and alveolar socket remains intact

Intervention type: PROCEDURE
Intervention: Tooth Extraction
Description: Tooth from the maxillary anterior area extracted and alveolar socket remains intact

Intervention type: PROCEDURE
Intervention: Tooth Extraction
Description: Tooth from the maxillary anterior area extracted and alveolar socket remains intact

Intervention type: RADIATION
Intervention: Cone-Beam technology evaluation
Description: Patient is submitted to a localized cone-beam image before tooth extraction and 6 month later, prior to implant installation.

Intervention type: RADIATION
Intervention: Cone-Beam technology evaluation
Description: Patient is submitted to a localized cone-beam image before tooth extraction and 6 month later, prior to implant installation.

Intervention type: RADIATION
Intervention: Cone-Beam technology evaluation
Description: Patient is submitted to a localized cone-beam image before tooth extraction and 6 month later, prior to implant installation.

Intervention type: OTHER
Intervention: Measure Alveolar Socket Remodeling
Description: In a computer, cone-beam images are superimposed to measure total the amount of ridge dimension

Intervention type: OTHER
Intervention: Measure Alveolar Socket Remodeling
Description: In a computer, cone-beam images are superimposed to measure total the amount of ridge dimension

Intervention type: OTHER
Intervention: Measure Alveolar Socket Remodeling
Description: In a computer, cone-beam images are superimposed to measure total the amount of ridge dimension
Study: NCT04296708

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Exergame Training
Description: An exergame combines exercise and gaming in a holistic approach.
Study: NCT03183115

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Radiofrequency ablation
Description: HALO360 System (Covidien GI Solutions, Sunnyvale, California, USA), which has been approved by the US Food and Drug Administration (FDA) and is approved for use in Europe (CE mark) and Taiwan (Ministry of Health and Welfare). Because the HALO 360 balloon catheter has been phased out since 2019, a new Barrx™ 360 Express catheter was used thereafter.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Endoscopy
Description: The participants will receive meticulous endoscopic examination with Lugol chromoendoscopy and Narrow-band imaging

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lugol's Solution (1.5%)
Description: Before the RFA intervention, the participants will received Lugol staining over the esophagus
Study: NCT01136252

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Adalimumab
Description: Intravitreal adalimumab injection (0,1 ml= 50 mcg) in the eye of the included patients. Patients will be followed up every week for a total of 4 weeks, and after every month until 6 months. If it is necessary, repeat the injection every month, maximum three months
Study: NCT01121939

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bevacizumab
Description: 15 mg/kg IV Day 1. The first dose should be administered over~90 minutes. If no adverse reactions occur after the initial dose, the second dose should~be administered over a minimum of 60 minutes. If no adverse reactions occur after the~second dose, all subsequent doses should be administered over a minimum of 30~minutes. Bevacizumab will be infused prior to pertuzumab.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pertuzumab
Description: 840 mg IV loading dose infused over 60 minutes. The loading dose is given on Cycle 1, Day 1 or as below. Subsequent doses of pertuzumab are 420 mg IV. If the patient tolerates the initial infusion over 60 minutes, the patient may receive subsequent infusions over 30 minutes. Otherwise, pertuzumab should be infused over 60 minutes. Patients should be observed for 30 minutes after completing the pertuzumab infusion.~If a patient misses a dose of pertuzumab for 1 cycle (i.e., 2 sequential cycles or administrations are 6 weeks or more apart), a re-loading dose (840 mg) of pertuzumab should be given. If re-loading pertuzumab is administered, subsequent doses of 420 mg will then be given every 3 weeks, starting 3 weeks later.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sandostatin LAR® Depot
Description: 30 mg will be given every 28 days by IM injection. The dose of sandostatin may be increased, at the discretion of the treating physician, if necessary to control symptoms related to tumor secretion of vasoactive peptides.
Study: NCT03974282

Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Psychological task
Description: Participants will complete a psychological task that evokes antisocially- and prosocially-motivated empathic responding

Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Psychological task
Description: Participants will complete a psychological task that evokes antisocially- and prosocially-motivated empathic responding
Study: NCT01228318

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Zoledronic acid
Description: 1. A single dose of reclast containing 5 mg/100 mL ready-to-infuse zoledronic acid solution administered over 15-30 minutes.~2. A single dose of placebo containing 220 mg mannitol and 24 mg sodium citrate in a 100 mL ready-to-infuse solution, administered over 15-30 minutes.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Zoledronic acid
Description: 1. A single dose of reclast containing 5 mg/100 mL ready-to-infuse zoledronic acid solution administered over 15-30 minutes.~2. A single dose of placebo containing 220 mg mannitol and 24 mg sodium citrate in a 100 mL ready-to-infuse solution, administered over 15-30 minutes.
Study: NCT02298426

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Health Management
Description: We provide large scales of weight management information included recipes according to people's constitution. Information is provide through both face to face meeting and telephones. Materials are also given to participants.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Health Management
Description: We provide large scales of weight management information included recipes according to people's constitution. Information is provide through both face to face meeting and telephones. Materials are also given to participants.

Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: General Management
Description: We provide general information about health. Information is provided through telephones and materials.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: General Management
Description: We provide general information about health. Information is provided through telephones and materials.

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: We use placebo to replace the health product.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Placebo
Description: We use placebo to replace the health product.

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: SCHSANDRA PLUS, YI RUI CAPSULE, Gest Aid Plus: INFINITUS®
Description: We use dietary supplement products to help balance the constitution of participants. Each participant got one of the three dietary supplement products. SCHSANDRA PLUS, INFINITUS® is a health product made of Schisandra, ginseng, Ginseng, Radix and other plant materials which can help enhance the body's antioxidant capacity. YI RUI CAPSULE , INFINITUS® is a health product made of salvia, hawthorn, alisma, perilla oil microcapsules, panax powder, ginkgo biloba and other plant materials which can assist lower the blood lipid level. Gest Aid Plus, INFINITUS® is a health product made of yam, codonopsis, poria, white beans, dried tangerine peel and other plant materials which can help regulate intestinal flora.

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: SCHSANDRA PLUS, YI RUI CAPSULE, Gest Aid Plus: INFINITUS®
Description: We use dietary supplement products to help balance the constitution of participants. Each participant got one of the three dietary supplement products. SCHSANDRA PLUS, INFINITUS® is a health product made of Schisandra, ginseng, Ginseng, Radix and other plant materials which can help enhance the body's antioxidant capacity. YI RUI CAPSULE , INFINITUS® is a health product made of salvia, hawthorn, alisma, perilla oil microcapsules, panax powder, ginkgo biloba and other plant materials which can assist lower the blood lipid level. Gest Aid Plus, INFINITUS® is a health product made of yam, codonopsis, poria, white beans, dried tangerine peel and other plant materials which can help regulate intestinal flora.
Study: NCT03789097

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pembrolizumab
Description: 200 mg administered as an IV infusion over 30 minutes Q3W

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Flt3L
Description: an immune cell growth factor. CDX-301 drug product is formulated as a sterile solution intended for single-use parenteral administration. Each vial contains a nominal 2.5 mg/mL CDX-301 protein in a 1 mL volume of buffered solution composed of sodium phosphate and sodium chloride, with a pH of 7.0.
Study: NCT02886039

Intervention type: OTHER
Group type: OTHER
Intervention: Electroencephalogram
Description: Prognostic evaluation of electroencephalogram score created with a retrospective cohort Creation of composite score to predict neurologic outcome in cardiorespiratory arrest
Study: NCT00756041

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TAK-128
Description: TAK-128 100 mg tablet, orally, once daily for up to 1 year.
Study: NCT03789097

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Radiation
Description: The target site will get 2 small treatments of radiation.